Enabling medical device vendors to realize the potential of the data collectible by their devices

Información del proyecto

bio-T

Identificador del acuerdo de subvención: 888653

DOI

10.3030/888653

Proyecto cerrado

Fecha de la firma de la CE 6 Noviembre 2019

Fecha de inicio 1 Diciembre 2019

Fecha de finalización 29 Febrero 2020

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

SOFTIMIZE LTD
Israel

Periodic Reporting for period 1 - bio-T (Enabling medical device vendors to realize the potential of the data collectible by their devices)

Período documentado: 2019-12-01 hasta 2020-02-29

Resumen del contexto y de los objetivos generales del proyecto

"The Internet of Medical Things (devices), a fast-growing multi-hundred billion dollar industry, is revolutionizing healthcare by enabling remote use of collected medical device data. BUT medical device manufacturers, eager to monetize on the data, face gaps in securing private patient data and designing remote care workflows. The involved risks (cyber, HIPAA/GDPR fines, cloud OPEX, usability, and time-to-market) lead vendors to turn to external solutions.
The device-agnostic bio-T remote clinical-care cloud platform, leveraging decades of technological IoT and cloud expertise of its founders, securely manages common yet complex remote care workflows. This ""undifferentiated heavy-lifting"" accelerates the transformation of medical device manufacturers from capital sales vendors into digital service providers while reducing their cyber, compliance and technological risks. bio-T is powering clients today, connecting thousands of FDA-cleared devices commercially, and accredited an ""AWS Advanced technology partner"".
The objectives of the bio-T project are focused on defining the technological, commercial and financial tasks to improve the platform’s performance from a technical perspective as well as ensuring that the platform meets and exceeds the basic requirements for adoption by IoMT stakeholders"

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

During the Feasibility Study, an in-depth study of the market was made to determine further market needs and the best go to market strategy. A detailed description of the next steps to follow to bring the innovation to commercialisation, such as: identification of activities and upgrades required to reach TRL9, work packages and budget preparation, definition of the full supply chain, definition of the business model and commercialisation strategy, risks and market analysis was made.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

In-house from-scratch development in medical device companies is our biggest competitor due to the relative ignorance about and the infancy of the IoMT platforms. However, their teams usually have very little experience in regulated cloud-native software and IoT. bio-T is ahead of the competition as they have both the expertise and market experience to cater to all the needs of Medtech manufacturers and vendors. bio-T is already powering FDA approved solutions and working on providing more functionality through adding deep device insights

Bio T logo